IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026
Enrollment in the Pivotal Phase 3 OVATION 3 Study Advances Company Toward Future…
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.,…